scholarly journals A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines

2013 ◽  
Vol 83 (4) ◽  
pp. 882-893 ◽  
Author(s):  
Katherine R. Singleton ◽  
Jihye Kim ◽  
Trista K. Hinz ◽  
Lindsay A. Marek ◽  
Matias Casás-Selves ◽  
...  
Keyword(s):  
Growth Factor ◽  
Growth Factor Receptor ◽  
Squamous Carcinoma ◽  
Fibroblast Growth Factor Receptors ◽  
Growth And Survival ◽  
Carcinoma Cell Lines ◽  
Epidermal Growth ◽  
Squamous Carcinoma Cell ◽  
Hepatocyte Growth ◽  
Viral Oncogene Homolog

scholarly journals Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

2013 ◽  
Vol 59 (10) ◽  
pp. 1447-1456 ◽  
Author(s):  
Michael J Duffy ◽  
John Crown
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Severe Toxicity ◽  
Viral Oncogene ◽  
Anaplastic Lymphoma ◽  
Epidermal Growth ◽  
Viral Oncogene Homolog

BACKGROUND Companion biomarkers are biomarkers that are used in combination with specific therapies and that prospectively help predict likely response or severe toxicity. In this article we review the role of companion biomarkers in guiding treatment in patients with cancer. CONTENT In addition to the established companion biomarkers such as estrogen receptors and HER2 (human epidermal growth factor receptor 2) in breast cancer, several new companion biomarkers have become available in recent years. These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti–epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non–small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. SUMMARY The availability of companion biomarkers should improve drug efficacy, decrease toxicity, and lead to a more individualized approach to cancer treatment.

scholarly journals Isoprocurcumenol Supports Keratinocyte Growth and Survival through Epidermal Growth Factor Receptor Activation

2021 ◽  
Vol 22 (22) ◽  
pp. 12579
Author(s):  
Paul Kwangho Kwon ◽  
Sung Wook Kim ◽  
Ranjit De ◽  
Sung Woo Jeong ◽  
Kyong-Tai Kim
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Receptor Activation ◽  
Cellular Damage ◽  
Major Type ◽  
Growth And Survival ◽  
Biosensor System ◽  
Key Factor ◽  
Epidermal Growth

Although proliferation of keratinocytes, a major type of skin cells, is a key factor in maintaining the function of skin, their ability to proliferate tends to diminish with age. To solve such a problem, researchers in medical and skin cosmetic fields have tried to utilize epidermal growth factor (EGF), but achieved limited success. Therefore, a small natural compound that can mimic the activity of EGF is highly desired in both medical and cosmetic fields. Here, using the modified biosensor system, we observed that natural small-compound isoprocurcumenol, which is a terpenoid molecule derived from turmeric, can activate EGFR signaling. It increased the phosphorylation of ERK and AKT, and upregulated the expression of genes related to cell growth and proliferation, such as c-myc, c-jun, c-fos, and egr-1. In addition, isoprocurcumenol induced the proliferation of keratinocytes in both physical and UVB-induced cellular damage, indicative of its function in skin regeneration. These findings reveal that EGF-like isoprocurcumenol promotes the proliferation of keratinocytes and further suggest its potential as an ingredient for medical and cosmetics use.

Sign in / Sign up

Export Citation Format

Share Document